Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease

NCT00240318 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00240318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00240318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2002
Completion date
November 30, 2005
Enrollment
450
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

coronary arteriosclerosis